Rajiv Dahiya

Dr. Rajiv Dahiya

Director, School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad & Tobago
orcid
Professor, School of Pharmacy, FMS, The University of the We...

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2017 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
YSYogendra Singh
Yogendra Singh
GGGaurav Gupta
Gaurav Gupta
BSBirendra Shrivastava
Birendra Shrivastava
Rajiv DahiyaRajiv Dahiya
Rajiv Dahiya
JTJuhi Tiwari
Juhi Tiwari
Kamal DuaKamal Dua
Kamal Dua

1 December 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
DCDinesh Kumar Chellappan
Dinesh Kumar Chellappan
NSNandhini S. Sivam
Nandhini S. Sivam
KTKai Xiang Teoh
Kai Xiang Teoh
WLWai Pan Leong
Wai Pan Leong
TFTai Zhen Fui
Tai Zhen Fui
Kamal DuaKamal Dua
Kamal Dua
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by T cell-mediated self-destruction of insulin-secreting islet β cells. Management of T1DM is challenging and complicated especially with conventional medications. Gene therapy has emerged as one of the potential therapeutic alternatives to treat T1DM. This review primarily focuses on the current status and the future perspectives of gene therapy in the management of T1DM. A vast number of the studies which are reported on gene therapy for the management of T1DM are done in animal models and in preclinical studies. In addition, the safety of such therapies is yet to be established in humans. Currently, there are several gene level interventions that are being investigated, notably, overexpression of genes and proteins needed against T1DM, transplantation of cells that express the genes against T1DM, stem-cells mediated gene therapy, genetic vaccination, immunological precursor cell-mediated gene therapy and vectors. We searched the current literature through searchable online databases, journals and other library sources using relevant keywords and search parameters. Only relevant publications in English, between the years 2000 and 2018, with evidences and proper citations, were considered. The publications were then analyzed and segregated into several subtopics based on common words and content. A total of 126 studies were found suitable for this review. Generally, the pros and cons of each of the gene-based therapies have been discussed based on the results collected from the literature. However, there are certain interventions that require further detailed studies to ensure their effectiveness. We have also highlighted the future direction and perspectives in gene therapy, which, researchers could benefit from.

26 October 2016 in Marine Drugs
Verified
Journal Article
Open access
PDF file
WFWan-Yin Fang
Wan-Yin Fang
Rajiv DahiyaRajiv Dahiya
Rajiv Dahiya
HQHua-Li Qin
Hua-Li Qin
RMRita Mourya
Rita Mourya
SMSandeep Bhupendra Maharaj
Sandeep Bhupendra Maharaj
Peptides have gained increased interest as therapeutics during recent years. More than 60 peptide drugs have reached the market for the benefit of patients and several hundreds of novel therapeutic peptides are in preclinical and clinical development. The key contributor to this success is the potent and specific, yet safe, mode of action of peptides. Among the wide range of biologically-active peptides, naturally-occurring marine-derived cyclopolypeptides exhibit a broad range of unusual and potent pharmacological activities. Because of their size and complexity, proline-rich cyclic peptides (PRCPs) occupy a crucial chemical space in drug discovery that may provide useful scaffolds for modulating more challenging biological targets, such as protein-protein interactions and allosteric binding sites. Diverse pharmacological activities of natural cyclic peptides from marine sponges, tunicates and cyanobacteria have encouraged efforts to develop cyclic peptides with well-known synthetic methods, including solid-phase and solution-phase techniques of peptide synthesis. The present review highlights the natural resources, unique structural features and the most relevant biological properties of proline-rich peptides of marine-origin, focusing on the potential therapeutic role that the PRCPs may play as a promising source of new peptide-based novel drugs.

25 February 2021 in Biology
Verified
Journal Article
Open access
PDF file
SFShivkanya Fuloria
Shivkanya Fuloria
Vetriselvan SubramaniyanVetriselvan Subramaniyan
Vetriselvan Subramaniyan
Rajiv DahiyaRajiv Dahiya
Rajiv Dahiya
SDSunita Dahiya
Sunita Dahiya
KSkalvatala sudhakar
kalvatala sudhakar
NFNeeraj Fuloria
Neeraj Fuloria
Evidence suggests that stem cells exert regenerative potential via the release of extracellular vesicles. Mesenchymal stem cell extracellular vesicles (MSCEVs) offer therapeutic benefits for various pathophysiological ailments by restoring tissues. Facts suggest that MSCEV action can be potentiated by modifying the mesenchymal stem cells culturing methodology and bioengineering EVs. Limited clinical trials of MSCEVs have questioned their superiority, culturing quality, production scale-up and isolation, and administration format. Translation of preclinically successful MSCEVs into a clinical platform requires paying attention to several critical matters, such as the production technique, quantification/characterization, pharmacokinetics/targeting/transfer to the target site, and the safety profile. Keeping these issues as a priority, the present review was designed to highlight the challenges in translating preclinical MSCEV research into clinical platforms and provide evidence for the regenerative potential of MSCEVs in various conditions of the liver, kidney, heart, nervous system, bone, muscle, cartilage, and other organs/tissues.

24 June 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Rajiv DahiyaRajiv Dahiya
Rajiv Dahiya
SDSunita Dahiya
Sunita Dahiya
NFNeeraj Fuloria
Neeraj Fuloria
SKSuresh Kumar
Suresh Kumar
RMRita Mourya
Rita Mourya
ASAjay Sharma
Ajay Sharma
Peptides are distinctive biomacromolecules that demonstrate potential cytotoxicity and diversified bioactivities against a variety of microorganisms including bacteria, mycobacteria, and fungi via their unique mechanisms of action. Among broad-ranging pharmacologically active peptides, natural marine-originated thiazole-based oligopeptides possess peculiar structural features along with a wide spectrum of exceptional and potent bioproperties. Because of their complex nature and size divergence, thiazole-based peptides (TBPs) bestow a pivotal chemical platform in drug discovery processes to generate competent scaffolds for regulating allosteric binding sites and peptide–peptide interactions. The present study dissertates on the natural reservoirs and exclusive structural components of marine-originated TBPs, with a special focus on their most pertinent pharmacological profiles, which may impart vital resources for the development of novel peptide-based therapeutic agents.

1 June 2007 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Rajiv DahiyaRajiv Dahiya
Rajiv Dahiya
DPDevender Pathak
Devender Pathak